5 documents found, page 1 of 1
Relapsing COVID-19 in a Patient With Non-Hodgkin Lymphoma on Chemotherapy
Carujo, A; Ferreira, L; Bergantim, R; Santos Silva, A; Vasconcelos, ALHematologic malignancies and chemotherapy are risk factors for COVID-19 progression and mortality. Immunocompromised hosts, particularly those with severe B-cell depletion, can shed viable viruses for extended periods, which can lead to persistent infection. We present the case of a 73-year-old male with diffuse large B-cell lymphoma (stage IV-B) under curative immunochemotherapy with rituximab, cyclophosphamid...
Lessons from Four Decades of Systemic Amyloidosis with Renal Involvement
Oliveira-Silva, C; Marques, N; Pinho, A; Poínhos, Rui; Bergantim, R; Nunes, AT; Sampaio, S; Rodrigues-Pereira, P; Silva, R; Praça, A; Frazão, JBackground: Apart from ATTR amyloidosis, the epidemiology and outcomes of the most common subtypes of systemic amyloidosis in Portugal remain primarily unknown. Methods: This retrospective cohort study evaluated patients with renal biopsy-proven amyloidosis, diagnosed from January 1978 to December 2019. Follow-up started at kidney disease presentation and ended at death or August 2020. Clinical presentation, su...
COVID-19 infection in adult patients with hematological malignancies: a Europea...
Pagano, L; Salmanton-García, J; Marchesi, F; Busca, A; Corradini, P; Hoenigl, M; Klimko, N; Koehler, P; Pagliuca, A; Passamonti, F; Verga, L; Víšek, BBackground: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Wor...
The Role of Extracellular Vesicles in the Hallmarks of Cancer and Drug Resistance
Xavier, CPR; Caires, HR; Barbosa, MAG; Bergantim, R; Guimarães, JE; Vasconcelos, MHExtracellular vesicles (EVs) mediate intercellular signaling and communication, allowing the intercellular exchange of proteins, lipids, and genetic material. Their recognized role in the maintenance of the physiological balance and homeostasis seems to be severely disturbed throughout the carcinogenesis process. Indeed, the modus operandi of cancer implies the highjack of the EV signaling network to support tu...
Multiple myeloma: Available therapies and causes of drug resistance
Pinto, V; Bergantim, R; Caires, HR; Seca, H; Guimarães, JE; Vasconcelos, MHMultiple myeloma (MM) is the second most common blood cancer. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors and monoclonal antibodies. Survival outcomes have improved substantially due to the introduction of many of these drugs allied with their rational use. Nonetheless, MM patients successively relaps...